MedTrace Logo

Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver

NCT00019760 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-10-31

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of melphalan given as an isolated hepatic perfusion followed by chemotherapy infused into the liver in patients who have unresectable colorectal cancer that is metastatic to the liver.

Conditions

  • Recurrent Colon Cancer
  • Liver Metastases
  • Stage IV Rectal Cancer
  • Recurrent Rectal Cancer
  • Stage IV Colon Cancer

Interventions

DRUG

floxuridine

DRUG

leucovorin calcium

DRUG

melphalan

Sponsors & Collaborators

  • National Institutes of Health Clinical Center (CC)

    lead NIH

Principal Investigators

  • H. Richard Alexander, Jr. · National Cancer Institute (NCI)

Study Design

Purpose
TREATMENT

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-04-30
Completion
2002-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00019760 on ClinicalTrials.gov